2025-08-20 - Analysis Report
Okay, here's an analysis of Johnson & Johnson (JNJ) based on the provided data, presented in English with a focus on key metrics and insights.

## Johnson & Johnson (JNJ) Stock Analysis

**Company Overview:** Johnson & Johnson is a global healthcare company engaged in the research, development, manufacture, and sale of a broad range of products in the healthcare field.

### 1. Performance vs. S&P 500 (VOO)

*   **JNJ Cumulative Return:** 29.64%
*   **VOO Cumulative Return:** 100.85%
*   **Absolute Deviation:** -68.9%
*   **Deviation Range:** Max: 13.9%, Min: -77.9%
*   **Relative Deviation:** 9.8% (This means the current deviation is near the bottom of its historical range relative to VOO)

**Analysis:** JNJ has significantly underperformed the S&P 500 (VOO) over the period analyzed.  The relative deviation suggests this underperformance is near the lowest point observed in the past.

**Alpha and Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha   | Beta   | Cap(B) |
|------------|--------|--------|---------|--------|--------|
| 2015-2017  | 28.0% | 56.1% | -1.0%   | -0.0 | 339.4  |
| 2016-2018  | 8.0%  | 56.6% | -10.0%  | 0.0 | 313.5  |
| 2017-2019  | 18.0% | 56.6% | -12.0%  | 0.7 | 354.4  |
| 2018-2020  | 12.0% | 59.2% | -8.0%   | 0.3 | 382.4  |
| 2019-2021  | 32.0% | 59.6% | -16.0%  | 0.2 | 415.6  |
| 2020-2022  | 7.0%  | 61.4% | 5.0%    | 0.2 | 429.2  |
| 2021-2023  | -15.0% | 61.4% | -33.0%  | 0.4 | 380.8  |
| 2022-2024  | -35.0% | 61.4% | -61.0%  | 0.3 | 351.4  |
| 2023-2025  | 2.0%  | 70.1% | -50.0%  | 0.2 | 428.2  |

**Analysis:**

*   **CAGR:** Compounded Annual Growth Rate is inconsistent, showing significant variability across different periods.
*   **MDD:** Maximum Drawdown values are high, indicating significant potential for loss during downturns.
*   **Alpha:** Alpha is mostly negative, indicating underperformance relative to a benchmark (likely the S&P 500).  The negative alpha trend is concerning.
*   **Beta:** Beta values are generally low, suggesting JNJ is less volatile than the overall market.
*   **Cap(B):** Market capitalization is substantial, ranging from approximately $313.5 billion to $429.2 billion.

### 2. Recent Price Action

*   **Current Price:** 176.25
*   **Last Market Data:** Price: 177.8, Previous Close: 176.25, Change: 0.88
*   **5-Day Moving Average:** 174.96
*   **20-Day Moving Average:** 170.72
*   **60-Day Moving Average:** 160.42

**Analysis:** The price is above all three moving averages, suggesting an upward trend in the short, medium, and long term. The small *change* value(0.88) showing steady growth.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.329 (Low Risk)
*   **RSI:** 71.83 (Overbought)
*   **PPO:** 0.1014
*   **Hybrid Signal:** Buy 80% of cash (1 shares - Caution - MRI:0.34)
*   **Delta Previous Relative Divergence (20-day):** -1.1 (Negative - Short-term Decrease)
*   **Expected Return (%):** -281.1% (Long-term, relative to S&P 500)

**Analysis:**

*   The MRI indicates a low-risk environment, which is a positive sign.
*   The RSI is in overbought territory, suggesting the stock may be due for a pullback.
*   The negative change in relative divergence indicates weakening performance compared to the benchmark.
*   The extremely negative expected return is highly concerning, indicating projected significant underperformance versus the S&P 500 over the long term.
*   The "Buy 80% of cash" signal, coupled with a "Caution" warning, suggests a moderately bullish outlook, tempered by the MRI score.

### 4. Recent News & Events

*   **[2025-08-16]:**  Major business developments, regulatory changes, or market events.
*   **[2025-08-17]:**  Analyst discussions on performance, industry trends, and global economic factors.
*   **[2025-08-19]:**  Notable volatility influenced by news, earnings, or executive actions.
*   **[2025-08-18]:**  Market experts highlighting risks and opportunities.

**Analysis:** The news suggests that JNJ is currently experiencing significant changes and increased volatility.  Investors should monitor news closely.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 매출        |
|------------|------|-------------|
| 2025-07-24 | 2.3  | 23.74 B$   |
| 2025-04-23 | 4.57 | 21.89 B$   |
| 2024-10-23 | 1.12 | 22.47 B$   |
| 2024-07-25 | 1.95 | 22.45 B$   |
| 2025-07-24 | 1.95 | 22.45 B$   |

**Analysis:**  Revenue has fluctuated, but is generally in the $22-24 billion range. EPS shows significant variation from quarter to quarter, suggesting inconsistency in profitability.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue    | Profit Margin |
|------------|------------|---------------|
| 2025-06-30 | $23.74B    | 67.87%        |
| 2025-03-31 | $21.89B    | 66.40%        |
| 2024-12-31 | $22.52B    | 68.35%        |
| 2024-09-30 | $22.47B    | 69.01%        |
| 2024-06-30 | $22.45B    | 69.40%        |

**Capital and Profitability:**

| Quarter    | Equity     | ROE    |
|------------|------------|--------|
| 2025-06-30 | $78.47B    | 7.06%  |
| 2025-03-31 | $78.11B    | 14.08% |
| 2024-12-31 | $71.49B    | 4.80%  |
| 2024-09-30 | $70.16B    | 3.84%  |
| 2024-06-30 | $71.54B    | 6.55%  |

**Analysis:**

*   **Revenue:** Relatively stable, with a slight increase in the most recent quarter.
*   **Profit Margin:** Consistently high, indicating strong profitability.
*   **Equity:** Increasing over the past few quarters.
*   **ROE:**  Volatile, with a significant spike in Q1 2025, followed by a drop in Q2 2025.  This fluctuation requires further investigation.

### 7. Overall Assessment

Based on the data provided, Johnson & Johnson (JNJ) presents a mixed picture:

*   **Negative Factors:**  Significant underperformance versus the S&P 500, negative alpha, concerningly negative expected return, overbought RSI, and fluctuating earnings.
*   **Positive Factors:**  Low MRI indicating low market risk, high profit margins, and recent upward price movement.

**Conclusion:** While JNJ demonstrates financial stability with high profit margins, the underperformance relative to the S&P 500 and the negative long-term expected return are significant concerns. The recent news indicating volatility and change warrants close monitoring. Investors should carefully weigh these factors before making investment decisions. The overbought RSI suggests potential for a short-term pullback. Further investigation into the cause of the ROE volatility is also recommended.

